Clinuvel Pharmaceuticals
(OTC) CLVLY
Clinuvel Pharmaceuticals Financials at a Glance
Market Cap
$370.52M
Revenue (TTM)
A$186.65M
Net Income (TTM)
A$71.12M
EPS (TTM)
$0.41
P/E Ratio
17.66
Dividend
$0.03
Beta (Volatility)
0.69 (Low)
Dividend
$0.03
Beta (Volatility)
0.69 (Low)
Price
$7.35
Volume
2,125
Open
$7.67
Price
$7.35
Volume
2,125
Open
$7.67
Previous Close
$7.35
Daily Range
$7.20 - $7.67
52-Week Range
$5.98 - $9.00
Estimated Earnings Date
Sep 1, 2026
Dividend
$0.03
Beta (Volatility)
0.69 (Low)
Price
$7.35
Volume
2,125
Open
$7.67
Previous Close
$7.35
Daily Range
$7.20 - $7.67
52-Week Range
$5.98 - $9.00
Estimated Earnings Date
Sep 1, 2026
CLVLY News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Clinuvel Pharmaceuticals
Industry
Biotechnology
Sector
Health CareCEO
Lachlan Hay
Website
www.clinuvel.comHeadquarters
Melbourne, VIC 3000, AU
CLVLY Financials
Key Financial Metrics (TTM)
Gross Margin
63.71%
Operating Margin
39.39%
Net Income Margin
33.79%
Return on Equity
13.29%
Return on Capital
18.95%
Return on Assets
12.07%
Earnings Yield
5.66%
Dividend Yield
0.45%
Payout Ratio
7.70%
Stock Overview
Market Cap
$370.52M
Shares Outstanding
50.41M
Volume
2.13K
Avg. Volume
2.07K
Financials (TTM)
Gross Profit
A$143.65M
Operating Income
A$89.29M
EBITDA
A$93.17M
Operating Cash Flow
A$64.06M
Capital Expenditure
-A$719.96K
Free Cash Flow
A$63.34M
Cash & ST Invst.
A$232.77M
Total Debt
A$340.75K
Clinuvel Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
A$36.25M
+12.4%
Gross Profit
A$20.37M
+20.4%
Gross Margin
56.19%
N/A
Market Cap
$370.52M
N/A
Market Cap/Employee
$3.71M
N/A
Employees
100
N/A
Net Income
A$10.25M
-6.3%
EBITDA
A$11.25M
-22.3%
Quarterly Fundamentals
Total Cash
A$232.77M
+33.4%
Total Debt
A$340.75K
-68.1%
Accounts Receivable
A$16.57M
+26.7%
Inventory
A$8.40M
-33.1%
Long Term Debt
A$34.46K
-95.2%
Short Term Debt
A$306.29K
-13.9%
Return on Assets
12.07%
N/A
Return on Invested Capital
15.06%
N/A
Free Cash Flow
A$12.15M
-42.4%
Operating Cash Flow
A$12.30M
-53.4%